Spanish payer Jaime Espín joins Omar Ali to discuss regulatory reform, transparency in pricing, and the evolving use of outcome-based payment models in Spain’s healthcare system.

Dutch HTA expert Hans Severens speaks with Omar Ali about value-based pricing, disease severity as a modifier, and the challenges of system sustainability in the Netherlands.

Italian AIFA member Fabrizio Gianfrate joins Omar Ali to discuss rare disease pricing, payment-over-time challenges, and the realities of reimbursement in the Italian healthcare system.

German payer Detlev Parow joins Verpora’s Omar Ali to discuss obesity, indication-based pricing, and risk-sharing models for gene therapies in one of Europe’s most complex healthcare systems.

Former CEPS member Jean-Claude Castanier joins Verpora’s Omar Ali to discuss France’s approach to multi-indication pricing, transparency, and long-term healthcare system sustainability.

Patient feedback changed the conversation on access for Botox in migraine care — watch how real-world insights reshaped value and future possibilities for innovative contracting.

How are payers responding when costly gene therapies don’t deliver long-term durability? We explore evolving contract models tackling buyer’s remorse in cell and gene therapy.

Turkey's new alternative reimbursement legislation aims to modernize its healthcare sector by promoting innovative contracting. It eases interactions with international pharmaceutical companies, ensures price confidentiality, and expedites product launches. However, Omar notes that companies are turning to these alternative methods due to challenges with Turkey's traditional reimbursement model, including high discounting rates. This shift is driving companies to develop more innovative contracting proposals for this alternative route.